Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis. - Liu Y; Yang SY; Zhang WH; Liang YT; Fu JW; Dai JY; Wu RL; Zheng CR; Wang HT; Li YH; Guo RQ; Zeng CM; et al. (Acta pharmacologica Sinica, 2026)